Synthesis and Distribution of Drugs of Abuse Tender - 141246046

Procurement Summary

Country: USA

Summary: Synthesis and Distribution of Drugs of Abuse and Related Compounds

Deadline: 28 May 2026

Posting Date: 14 May 2026

Other Information

Notice Type: Tender

TOT Ref.No.: 141246046

Document Ref. No.: 75N95022D00016

Competition: ICB

Financier: Self Financed

Purchaser Ownership: Public

Tender Value: Refer Document

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_details

Login to see details

Tender Details

INTRODUCTION
PURSUANT TO FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A NOTICE OF A PROPOSED CONTRACT ACTION.
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022D00016 WITH RESEARCH TRIANGLE INSTITUTE.
The National Institute on Drug Abuse (NIDA) Division of Therapeutics and Medical Consequences (DTMC) at the National Institutes of Health (NIH) intends to modify the Single Award Indefinite Delivery, Indefinite Quantity (IDIQ) Contract No. 75N95022D00016 “Synthesis and Distribution of Drugs of Abuse and Related Compounds” to increase the Single Award IDIQ maximum by $3, 718, 289 from $14, 004, 330 to $17, 722, 619 during the five (5) year ordering period from June 9, 2022 to June 8, 2027; there are no other changes.
The increase to the IDIQ maximum will allow for the continuation of work begun under the Synthesis and Distribution of Drugs of Abuse and Related Compounds contract and prevent any delays or disruption of support services for scientific research working on problems of substance use and drug dependence with authentic and pure supplies of controlled drugs and research chemicals essential for ongoing and upcoming pre-clinical and clinical trials while a new contract is properly planned and competed. To support efforts in addressing the national public health crisis from substance use, NIDA through this contract modification also addresses an increased need for drug product to support clinical trials. The increase in the IDIQ maximum will, therefore, allow for the continuation of work initiated under this contract in addition to purchasing drug product to support new and ongoing clinical trials.
The contract provides contract support services in the following areas to:
Produce and distribute labeled and unlabeled drugs of abuse and other research compounds to researchers as approved by the NIDA COR;
Analyze, test, and maintain the purity of drugs of abuse and other chemical compounds i...
Notice ID: 75n95022d00016

Department/Ind. Agency: health and human services, department of

Sub-tier: national institutes of health

Office: national institutes of health nida

Product Service Code: an11 - health r&d services; health care services; basic research

NAICS Code: 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Inactive Dates: jun 12, 2026

Inactive Policy: 15 days after response date

Documents

 Tender Notice